Paid Clinical Trials in Fort Wayne, IN
As of July 2026, 103 paid clinical trials are recruiting in Fort Wayne, Indiana. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Fort Wayne offers studies at sites including Fort Wayne Medical Oncology and Hematology for conditions such as Breast Cancer, Endometrial Cancer, Ovarian Cancer, Carcinoma, Non-Small-Cell Lung. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Fort Wayne
Trials by drug in Fort Wayne
Filter results
Newly added in Fort Wayne
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
98 clinical trials
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
Prevail Global Study
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Top Research Study Locations in Fort Wayne
Researchers run research studies in Fort Wayne, IN at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Fort Wayne Medical Oncology and Hematology | Breast Cancer, Melanoma, Advanced Cancer | 16 |
| Parkview Research Center | Endometrial Cancer, Ovarian Cancer, Prostate Cancer | 13 |
| Parkview Regional Medical Center | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8 | 8 |
| Parkview Research Center at Parkview Regional Medical Center | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Carcinoma, Transitional Cell | 8 |
| Parkview Health | Aortic Stenosis, Breast Cancer, Coronary Artery Disease | 4 |
| Fort Wayne Medical Oncology and Hematology, Inc | Carcinoma, Non-Small Cell Lung, Cutaneous Squamous Cell Cancer, Esophageal Adenocarcinoma | 3 |
| GSK Investigational Site | Neoplasms, Neoplasms, Head and Neck | 2 |
| Lutheran Medical Group | Arteriovenous Fistula, Catheter Complications, Catheter Dysfunction | 2 |
| Parkview Cancer Institute | Chemo Fog, Chemo-brain, Chemotherapy Effect | 2 |
| Parkview Packnett Family Cancer Institute | Metastatic Bone Disease, Metastatic Non-small Cell Lung Cancer | 2 |
| Salus Research, Inc. | Gingivitis, Dental Plaque, Plaque | 2 |
| Orthopaedics NorthEast | Degenerative Disc Disease, Lumbar Disc Disease, Lumbar Spine Degeneration | 2 |
| American Oncology Partners | B-cell Malignancy, Chronic Lymphocytic Leukemia, Follicular Lymphoma | 1 |
| Clinical Study Site | Metastatic Colorectal Cancer (CRC) | 1 |
| Dupont Hospital | Cartilage Damage, Cartilage Defects of the Knee, Cartilage Lesion | 1 |
| Ep0162 50504 | Stereotypical Prolonged Seizures | 1 |
| Ep0165 50504 | Stereotypical Prolonged Seizures | 1 |
| Fort Wayne Center for Children and Families | Conflict, Mental Health | 1 |
| Fort Wayne Medical Oncology & Hematology | Colorectal Neoplasms | 1 |
| Fort Wayne Medical Oncology - 1133 | Non Small Cell Lung Cancer | 1 |
| Fort Wayne Medical Oncology Hematology | Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion | 1 |
| Fort Wayne Medical Oncology and Hematology, Inc. | Non-small Cell Lung Cancer | 1 |
| Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne North Office | Neuroendocrine Carcinomas, Small-cell Lung Cancer, Solid Tumor Show to Express DLL3 | 1 |
| Fort Wayne Medical Oncology and Hematology- South Office | Follicular Lymphoma (FL) | 1 |
| Fort Wayne Oncology and Hematology | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 1 |
Active & Upcoming Studies in Fort Wayne (2026)
Recruiting trials in Fort Wayne grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (65 active studies)
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease · Phase 3 · BeOne Medicines
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) · Phase 3 · Astellas Pharma Global Development, Inc.
Cardiovascular (4 active studies)
- A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) · Phase 2 · Pfizer
- Prevail Global Study · Medtronic Vascular
Neurology & pain (2 active studies)
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 · Phase 3 · Rapport Therapeutics Inc.
- BioPoly® Partial Resurfacing Knee Implant IDE · BioPoly LLC
Common conditions studied in Fort Wayne
- Breast Cancer (6 active studies)
- Endometrial Cancer (5 active studies)
- Ovarian Cancer (5 active studies)
- Carcinoma, Non-Small-Cell Lung (4 active studies)
- Non-small Cell Lung Cancer (4 active studies)
- Gingivitis (3 active studies)
Leading research sponsors in Fort Wayne
- AstraZeneca
- Merck Sharp & Dohme LLC
- AbbVie
- Bristol-Myers Squibb
- Eli Lilly and Company
Frequently asked questions
How many paid clinical trials are currently recruiting in Fort Wayne?
There are approximately 103 recruiting clinical trials in Fort Wayne, Indiana listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Fort Wayne pay participants?
Most recruiting trials in Fort Wayne compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Fort Wayne?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Fort Wayne?
The most common conditions under active study in Fort Wayne include Breast Cancer (6), Endometrial Cancer (5), Ovarian Cancer (5), Carcinoma, Non-Small-Cell Lung (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Fort Wayne?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Fort Wayne on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Fort Wayne?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Fort Wayne?
Recruiting research sites in Fort Wayne include Fort Wayne Medical Oncology and Hematology, Parkview Research Center, Parkview Regional Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Fort Wayne right now?
The largest active categories in Fort Wayne are Cancer & tumors (65), Cardiovascular (4), Neurology & pain (2). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.